Today

Agents

Chat

Arena

Discover

More

App

Spyre Therapeutics Announces Launch Of Spy772 Program - SYRE News | Rallies

Spyre Therapeutics Announces Launch Of Spy772 Program

SYRE•2026-08-10

Spyre launches Spy772 program and Phase 2 trial

Aug. 10 (Reuters) - Spyre Therapeutics Inc SYRE.O:

Spyre Therapeutics announces launch of the Spy772 program and initiation of Phase 2 Skylight trial in hidradenitis suppurativa.

Source text: ID:nGNXc3dzRL

Further company coverage: SYRE.O

Related News

Daktronics CEO, acting CFO to join Needham virtual industrial tech conference 1x1 meetings

DAKT•2026-08-10

FOREX-Dollar gains, yen weakens as markets eye US CPI

SPY•2026-08-10

BUZZ-Csquare edges higher as research quiet period ends with mostly bullish calls

•

2026-08-10

Nasdaq trade halt <SCKT.O> volatility trading pause at 10:49 AM

SCKT•2026-08-10

Global markets-Oil prices jump, Wall Street and European shares under pressure with Hormuz, inflation in focus

SPY•2026-08-10